Get the Stockscreener App
1.30
6.47%
-0.09
Pre-market:
1.29
-0.01
-0.77%
Oragenics Inc stock is traded at $1.30, with a volume of 165.09K.
It is down -6.47% in the last 24 hours and up +14.54% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$1.39
Open:
$1.39
24h Volume:
165.09K
Relative Volume:
0.86
Market Cap:
$5.37M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.1522
EPS:
-8.54
Net Cash Flow:
$-8.25M
1W Performance:
-0.76%
1M Performance:
+14.54%
6M Performance:
-75.52%
1Y Performance:
-88.80%
1-Day Range:
$1.28
$1.40
1-Week Range:
$1.26
$1.45
52-Week Range:
$1.01
$18.90
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
1.30 | 5.74M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Oragenics Inc Stock (OGEN) Latest News
How to use Fibonacci retracement on Oragenics Inc.Dip Buying & Long-Term Capital Growth Strategies - newser.com
Will Oragenics Inc. bounce back from current supportDay Trade & Weekly Breakout Watchlists - newser.com
Is Oragenics Inc. meeting your algorithmic filter criteria2025 Major Catalysts & Verified Momentum Stock Alerts - newser.com
Why Oragenics Inc. stock could benefit from AI revolutionJuly 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Applying Wyckoff theory to Oragenics Inc. stockMarket Risk Summary & Reliable Intraday Trade Alerts - newser.com
What’s the recovery path for long term holders of Oragenics Inc.Quarterly Profit Report & Growth Focused Entry Reports - newser.com
Why Oragenics Inc. stock fits value portfoliosJuly 2025 Summary & Daily Stock Trend Reports - newser.com
What machine learning models say about Oragenics Inc.2025 Support & Resistance & Daily Profit Maximizing Trade Tips - newser.com
Using economic indicators to assess Oragenics Inc. potentialTrade Performance Summary & AI Optimized Trade Strategies - newser.com
Is Oragenics Inc. stock attractive for growth ETFs2025 Biggest Moves & Fast Moving Market Watchlists - newser.com
Oragenics partners Receptor.AI for brain health candidate portfolio - Yahoo Finance
Oragenics Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics - citybuzz
Press Telegram - FinancialContent
Oragenics (OGEN) Collaborates with Receptor.AI for Drug Developm - GuruFocus
Oragenics (OGEN) Partners with Receptor.AI to Enhance Drug Devel - GuruFocus
Oragenics partners with Receptor.AI to expand brain therapeutics pipeline By Investing.com - Investing.com Australia
Oragenics announces strategic partnership with Receptor.AI to accelerate pipeline development - MarketScreener
Oragenics partners with Receptor.AI to expand brain therapeutics pipeline - Investing.com
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development - MarketScreener
Can Oragenics Inc. stock beat analyst consensusLong Setup & Free Growth Oriented Trading Recommendations - newser.com
Will Oragenics Inc. stock beat Nasdaq index returnsPortfolio Gains Report & Real-Time Sentiment Analysis - newser.com
Trend analysis for Oragenics Inc. this weekJuly 2025 PreEarnings & Reliable Breakout Stock Forecasts - newser.com
Will Oragenics Inc. stock benefit from mergersExit Point & Weekly Momentum Picks - newser.com
A activity2025 Winners & Losers & Technical Entry and Exit Tips - newser.com
Oragenics Inc Stock Analysis and ForecastInstitutional Buying Trends & Superior Capital Investment - earlytimes.in
Can Oragenics Inc. hit a new high this monthJuly 2025 Pullbacks & Expert Verified Movement Alerts - newser.com
Measuring Oragenics Inc.’s beta against major indicesTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com
Is Oragenics Inc. stock testing key support2025 Institutional Moves & Short-Term Trading Alerts - newser.com
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):